Warm Autoimmune Hemolytic Anemia – Executive Insights – Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5 | 2022

Warm autoimmune hemolytic anemia (WAIHA), a type of autoimmune hemolytic anemia, is caused by increased erythrocyte destruction by IgG autoantibodies. Increasing the hemoglobin level to > 10 g/dL is the primary goal of treatment. With no approved drug therapy, corticosteroids, rituximab, and immunosuppressants form the mainstay of treatment for WAIHA. Two oral agents (Rigel’s fostamatinib and Incyte’s parsaclisib) and an antibody (J&J’s nipocalimab) are in Phase III development and lead the race to reach the market for the treatment of WAIHA. With a strong drug pipeline, the treatment landscape for WAIHA is expected to change significantly over the next ten years. The new drugs are not expected to replace the current standard of care, but they will carve out a niche for themselves by targeting certain subpopulation segments. With no approved drugs for WAIHA, drug developers have an opportunity to address this significant unmet need.

QUESTIONS ANSWERED

  • What are the disease incidence and prevalence?
  • What is the current standard of care for WAIHA treatment? What is the treatment gap?
  • What are the key unmet needs? How can they be addressed by pipeline agents?
  • What are the emerging therapies in development for WAIHA? When are they forecast to launch, and what are the estimated costs of treatment in different geographies?
  • What are the key market drivers and limiters?
  • What are the opinions of KOLs on different aspects of WAIHA?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

GEOGRAPHY: United States, EU5

PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022

KEY COMPANIES COVERED: Janssen Research & Development, Sanofi, Rigel Pharmaceuticals, Incyte, Annexon

KEY DRUGS COVERED: Fostamatinib, nipocalimab, parsaclisib, isatuximab, rilzabrutinib, ANX005

Table of contents

  • Warm Autoimmune Hemolytic Anemia - Executive Insights - Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5 | 2022
    • Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5

Login to access report

launch Related Market Assessment Reports